Show simple item record

dc.contributor.authorAparicio Gallego, Guadalupe
dc.contributor.authorBlanco, Moisés
dc.contributor.authorFigueroa, Angélica
dc.contributor.authorGarcía-Campelo, Rosario
dc.contributor.authorValladares-Ayerbes, Manuel
dc.contributor.authorGrande Pulido, Enrique
dc.contributor.authorAntón-Aparicio, Luis M.
dc.date.accessioned2018-04-10T10:41:08Z
dc.date.available2018-04-10T10:41:08Z
dc.date.issued2011-12
dc.identifier.citationAparicio-Gallego G, Blanco M, Figueroa A, et al. New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther. 2011; 10(12):2215-23es_ES
dc.identifier.issn1535-7163
dc.identifier.issn1538-8514
dc.identifier.urihttp://hdl.handle.net/2183/20418
dc.descriptionReviewes_ES
dc.description.abstract[Abstract] The introduction of targeted therapy represents a major advance in the treatment of tumor progression. Targeted agents are a novel therapeutic approach developed to disrupt different cellular signaling pathways. The tyrosine kinase inhibitor sunitinib specifically blocks multiple tyrosine kinase receptors that are involved in the progression of many tumors. Sunitinib is the current standard of care in first-line treatment of advanced renal cell carcinoma, and it is approved in imatinib-intolerant and imatinib-refractory gastrointestinal stromal tumors. However, it is increasingly evident that sunitinib may display collateral effects on other proteins beyond its main target receptors, eliciting undesirable and unexpected adverse events. A better understanding of the molecular mechanisms underlying these undesirable sunitinib-associated side effects will help physicians to maximize efficacy of sunitinib and minimize adverse events. Here, we focus on new insights into molecular mechanisms that may mediate sunitinib-associated adverse events.es_ES
dc.language.isoenges_ES
dc.publisherAmerican Association for Cancer Researches_ES
dc.relation.urihttp://dx.doi.org/10.1158/1535-7163.MCT-10-1124es_ES
dc.subjectAntineoplastic agentses_ES
dc.subjectCarcinoma, Renal celles_ES
dc.subjectHypertensiones_ES
dc.subjectHypothyroidismes_ES
dc.subjectIndoleses_ES
dc.subjectKidney neoplasmses_ES
dc.subjectPigmentation disorderses_ES
dc.subjectPyrroleses_ES
dc.subjectSignal transductiones_ES
dc.titleNew insights into molecular mechanisms of sunitinib-associated side effectses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleMolecular Cancer Therapeuticses_ES
UDC.volume10es_ES
UDC.issue12es_ES
UDC.startPage2215es_ES
UDC.endPage2223es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record